oncocidin a1

Oncocidin A1 is a **small molecule tubulin inhibitor** with antitumor activity, initially developed by SRI International. It is a structural analog of thyroid hormone that inhibits the proliferation of human carcinoma cells and the growth of breast (MDA MB-231) and ovarian (OVCAR-3) carcinoma xenografts in mouse models[1][4]. The mechanism involves binding to the colchicine site on tubulin, thereby **disrupting microtubule assembly**; this action causes cell cycle arrest in prometaphase (G2/M arrest) and triggers apoptosis through cytotoxic effects on mitotic spindle function[1][4]. It is orally bioavailable, well tolerated in animal models, and demonstrates antitumor efficacy with reduced normal tissue toxicity upon oral administration[1]. It is structurally related to combretastatin A-4 and is considered a lead for a new class of microtubule-binding anticancer agents[1]. Oncocidin A1 has been primarily evaluated in **breast cancer, ovarian cancer, and potentially other neoplastic conditions**[1][4].

Other names

methyl-3,5-diiodo-4-(4'-methoxyphenoxy)benzoate